Richter Gedeon Nyrt

What Richter Gedeon Nyrt does

Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company founded in 1901 by pharmacist Gedeon Richter, listed on the Budapest Stock Exchange as a leading blue-chip. The company manufactures more than 200 drugs (originals, generics, and licensed products) across four business units: Neuropsychiatry (anchored by cariprazine/Reagila), Biotechnology (biosimilars and CDMO services through Richter BioLogics), Women's Healthcare (contraception, fertility, endometriosis, menopause, uterine fibroids, HRT), and General Medicines (cardiometabolic, CNS, rheumatology generics). It operates with 12,000+ employees, of which 1,200+ are in R&D — the largest pharmaceutical research centre in Central Eastern Europe — spending over 7% of revenue on R&D and leveraging in-house active ingredient manufacturing and internationally recognised steroid chemistry expertise.

The company sells through direct subsidiaries and representative offices in 100+ countries across Europe, CIS, Americas, Asia-Pacific, and Oceania, complemented by channel partnerships (Hikma for US biosimilars, Hetero Labs for Semaglutide in US and emerging markets, Acrux for Lenzetto in Australia, AbbVie co-development for neuropsychiatry). FY2025 revenue reached HUF 914 billion (~EUR 2.3 billion) with 14% clean EBIT growth, and FY2026 guidance points to high single-digit revenue growth. Recent strategic activity is heavily concentrated on portfolio expansion in women's healthcare (Celmatix acquisition, FimmCyte FMC2 collaboration) and entry into GLP-1 therapeutics (Semaglutide partnership with Hetero), alongside biosimilar approvals such as Tuyory's CHMP positive opinion. The company also offers CDMO services for biologics and runs a biosimilar licensing business that monetises its manufacturing scale through partners like Hikma.

Name

Richter Gedeon Nyrt

Legal name

Richter Gedeon Vegyészeti Gyár Nyilvánosan Működő Rt.

Website

https://gedeonrichter.com

Company type

Public

Founded year

1901

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company (founded 1901) that manufactures 200+ drugs across neuropsychiatry, women's healthcare, biosimilars, and general medicines, selling in 100+ countries with HUF 914B FY2025 revenue.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Specialty pharmaceuticals
• Biosimilar development
• Women's healthcare drugs
• Neuropsychiatry medicines
• Active pharmaceutical ingredients

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices18 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Richter generates revenue primarily through the manufacture and sale of pharmaceutical products including original, generic, and licensed drugs across CNS, cardiovascular, gynaecological, and general medicine therapeutic areas. The company manufactures more than 200 drugs sold in 100+ countries through direct subsidiaries and distribution partners.
2. Licensed and Co-Development Products: Revenue from licensed products (e.g., Lenzetto transdermal estradiol spray licensed to Acrux for Australia, Reagila schizophrenia treatment acquired from Recordati), and co-development partnerships including global collaboration with Hetero Labs for Semaglutide and partnership with AbbVie for neuropsychiatric treatments.
3. CDMO / Contract Manufacturing Services: Through its biotechnology business unit, Richter offers contract development and manufacturing (CDMO) services for biosimilars and biologic products, including manufacturing denosumab biosimilars for Hikma under a 2021 license and commercialization agreement.
4. Biosimilar Licensing: Revenue from out-licensing biosimilar products developed and manufactured by Richter, with Hikma holding exclusive US commercialization rights for denosumab biosimilars Enoby and Xtrenbo.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Richter Gedeon Nyrt is a vertically integrated specialty pharmaceutical company that manufactures and markets more than 200 drugs including original, generic, and licensed products across CNS, cardiovascular, women's healthcare, and biosimilar therapeutic areas. The company operates in-house API manufacturing, conducts original NCE research, runs CDMO services through Richter BioLogics, and distributes products to healthcare providers and patients in 100+ countries through direct subsidiaries and channel partners.

Product overview

Gedeon Richter is a Hungarian-headquartered pharmaceutical company founded in 1901, operating as a vertically integrated specialty pharmaceutical company involved in manufacturing, R&D, sales and marketing. The company manufactures more than 200 drugs including original, generic and licensed products providing effective treatments in central nervous system (CNS), cardiovascular, and gynecological (Women's Healthcare) therapeutic areas. The product portfolio is organized around four main business units: Neuropsychiatry (led by Cariprazine/Reagila), Biotechnology (including CDMO services and biosimilars), Women's Healthcare (spanning contraception, fertility, endometriosis, menopause, uterine fibroids, vaginal infections, and HRT), and General Medicines (generic medications for cardiometabolic, CNS, and rheumatology). The company's strategy emphasizes original research, women's healthcare, and biosimilars, with key products including Cariprazine for schizophrenia, Tuyory (tocilizumab biosimilar), denosumab biosimilars (Enoby/Xtrenbo), Ryeqo, and Lenzetto. Recent portfolio expansion includes acquired assets from Celmatix (fertility/endometriosis/ovarian aging programs) and partnership-enabled products like the Semaglutide generic (with Hetero Labs) and FMC2 (with FimmCyte).

Differentiator

Problem solved

Functional benefit

Brands

• Enoby: Denosumab biosimilar referencing Amgen's Prolia, manufactured by Gedeon Richter under Hikma license for US market.
• Xtrenbo

Products and services

• Cariprazine (Reagila) Cariprazine is an original research compound developed by Gedeon Richter for the treatment of central nervous system disorders, including schizophrenia and bipolar disorder. Marketed as Reagila in multiple markets.
• Lenzetto (transdermal estradiol spray) Transdermal estradiol spray for menopausal hormone therapy, licensed to Acrux Limited for distribution in Australia and additional territories.
• Tuyory (tocilizumab biosimilar) Richter's own biosimilar tocilizumab product, branded Tuyory, intended for multiple indications corresponding to the originator biologic. Received positive CHMP opinion in 2026.
• Enoby (denosumab biosimilar) Denosumab biosimilar referencing Amgen's Prolia for osteoporosis treatment, manufactured by Gedeon Richter and commercialized in the US by Hikma under exclusive US commercialization rights.
• Xtrenbo (denosumab biosimilar) Denosumab biosimilar referencing Amgen's Xgeva for bone cancer-related complications, manufactured by Gedeon Richter and commercialized in the US by Hikma.
• Ryeqo Combination therapy for symptoms of uterine fibroids and endometriosis in women of reproductive age.
• Biotechnology / CDMO Services Contract development and manufacturing organization (CDMO) services for biosimilars and biological drugs, delivered through Richter BioLogics GmbH in Hamburg, covering development, manufacture, and commercialization support for biologic products.

Quantifiable outcome

• 14% growth in clean EBIT in fiscal year 2025
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Hetero Labs Ltd.coreStrategic or Co-development Partner · 10 June 2026Global collaboration agreement between Gedeon Richter and India-based Hetero Labs for the joint development, registration, and commercialization of Semaglutide Injection (generic version of Ozempic). The partnership combines Hetero's market reach in the US and emerging markets with Richter's commercial network across Europe and Central Asia under a cost- and profit-sharing model. Regulatory filings are planned for 2027 in the EU and US.
• Acrux LimitedminorChannel Partner/ Reseller/ Distributor · 27 May 2026Gedeon Richter and Acrux Limited extended the license agreement dated 2 May 2013 relating to the transdermal Estradiol spray Lenzetto (menopause hormone therapy) to cover an additional commercially significant territory.
• CelmatixcoreStrategic or Co-development Partner · 4 March 2026Richter acquired the women's health drug discovery portfolio from US biotech Celmatix, adding three early-stage programs spanning fertility, endometriosis, and ovarian aging to its pipeline. Celmatix receives upfront and milestone payments as development progresses. The deal signals ovarian biology emerging as an investable area within longevity science.
• FimmCytecoreStrategic or Co-development Partner · 18 February 2026Swiss biotech FimmCyte entered a strategic research collaboration and option-to-license agreement with Gedeon Richter to advance its first-in-class, non-hormonal antibody treatment FMC2 for endometriosis. Joint R&D toward first-in-human clinical studies with Richter holding an exclusive option on global rights exercisable before first clinical trial. Richter operates Central Europe's largest R&D hub. FimmCyte eligible for development and commercial milestone payments plus tiered royalties.
• Recordati PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 17 February 2026Gedeon Richter UK acquired rights to the schizophrenia treatment Reagila from Recordati Pharmaceuticals, expanding the CNS portfolio in the UK market.
• AbbViecoreStrategic or Co-development Partner · 1 January 2024AbbVie entered a co-development agreement with Gedeon Richter for novel neuropsychiatric treatments, expanding Richter's CNS pipeline through strategic partnership with a major global pharmaceutical company.
• Hikma PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 January 2021UK-headquartered Hikma Pharmaceuticals and its US subsidiary launched two denosumab biosimilars (Enoby and Xtrenbo) in the US market, referencing Amgen's Prolia and Xgeva. Products are manufactured by Gedeon Richter under a 2021 license and commercialization agreement, with Hikma holding exclusive US commercialization rights.
• Judit PolgárminorGTM or Marketing PartnerLong-standing partnership between Gedeon Richter and chess legend Judit Polgár, demonstrated at Chessparty Stockholm (April 17-18 at Avicii Arena). The partnership draws parallels between elite chess and business leadership, with thousands of children and young people attending to play chess and meet role models. Mats Jonsson, Manager of Gedeon Richter Nordics, represented the company at the event.
• Semmelweis UniversityminorGTM or Marketing PartnerThe Semmelweis-Richter Journalism Award 2026, jointly awarded by Semmelweis University and Gedeon Richter, recognises outstanding journalism on health topics in Europe. Total prize of 45,000 EUR across two categories (Women's Health and Pharma Strategies and Innovation). Winners to be announced in the last week of July 2026.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Market position

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCOwfsQuXoGjRCWpVDefzzZg
• Facebookfacebook.com/richterkarrier
• LinkedInlinkedin.com/company/richter-gedeon-hungary

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries44 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Richter Gedeon Nyrt